Episodit
-
Generative AI represents a paradigm shift in the landscape of healthcare, offering unprecedented potential to revolutionize patient care, diagnosis, and treatment methodologies. However, amid its promising advancements substantial and daunting risks remain. Dr. Hanjie Zhang, Senior Director of computational statistics and artificial Intelligence at the Renal Research Institute in New York discusses the benefits and risks of Generative AI in healthcare.
-
Puuttuva jakso?
-
Michelle Carver, Chief Nursing Officer and Senior Vice President of Nursing and Clinical Services at Fresenius Kidney Care discusses the benefits and challenges of patients dialyzing at home.
-
Luca Neri, Senior Director of Clinical Advanced Analytics at Fresenius Medical Care, discusses Anemia Management with AI and computational modeling.
-
Integrated evidence-generation represent a fundamental shift in the way evidence is generated across functions, geographies, and phases of the product or asset life cycle, and as such entails considerable effort to implement. Manuela Stauss-Grabo, PhD, leads the Global Biomedical Evidence Generation Team within Fresenius Medical Care’s Global Medical Office.
-
Rachel Meyer the Strategic Policy Advisor at the American Society of Nephrology and Sharon Pearce, Senior Vice President of Governance Affairs at National Kidney Foundation discuss the changes in U.S. policy regarding organ transplantation.
Organ Procurement and Transplantation Network (OPTN) Modernization Initiative: https://www.hrsa.gov/optn-modernization
“Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United States” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216615/
“Disparities in kidney transplant waitlisting among young patients without medical comorbidities” https://pubmed.ncbi.nlm.nih.gov/37782509/
“Patient Preferences for Waiting Time and Kidney Quality” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625104/
H.R.2923 - Living Donor Protection Act of 2023: https://www.congress.gov/bill/118th-congress/house-bill/2923?s=1&r=9
National Living Donor Assistance Center (NLDAC): https://www.livingdonorassistance.org/
H.R.6171 - Living Organ Donor Tax Credit Act of 2023: https://www.congress.gov/bill/118th-congress/house-bill/6171
-
By combining clinical and patient-reported end points, the CONVINCE trial is unique and affords opportunities for improving patient health status and treatment goals.
Krister Cromm, Fresenius Medical Care’s Director Person-Centered Outcomes Research, discuss the company’s evolution from disease-centered to person-centered integrated trial design.
-
David Rhew, Microsoft’s Chief Medical Officer and Vice President of Healthcare, discusses ChatGPT’s uses in healthcare.
-
Dr. Brigitte Schiller, Fresenius Medical Care’s senior vice president for home therapies, discusses the ecosystem and opportunities for patients to do dialysis in their own home.
-
Investigators from Wake Forest University and the Renal Research Institute are conducting a study, funded by PCORI, to find out if an incremental HD treatment plan is safe and beneficial to patients with residual kidney function. Jochen Raimann, the director of data analytics for the Renal Research Institute, discusses the study and its potential benefits for patients.
-
Dr. Isaac “Zak” Kohane, Chair of the Department of Biomedical Informatics at Harvard Medical School discusses the adoption of artificial intelligence and machine learning in healthcare.
-
Dr. Dr. Vivekanand Jha, Executive Director, of The George Institute for Global Health in India discusses health inequality and how it manifests in communities.
-
A growing body of evidence demonstrates that connected health technologies make healthcare more effective and efficient. Connected health delivers many benefits including expanded access to care, safety, better disease management, improved medication adherence, and reduced hospitalizations and readmissions. Dr. Shelly Nash Senior Vice President and Chief Medical Information Officer
for the Global Medical Office at Fresenius Medical Care discusses the benefits of connected health.
-
Prof. Peter Blankestijn discusses the results of the multi-center CONVINCE Study including how the use of hemodiafiltration impacts patient morbidity and all-cause mortality as well as patient-reported outcomes. The results were presented at the ERA EDTA conference in June of 2023.
-
APOL1-c is a kidney disorder associated with certain APOL1 genetic mutations, often found in people of Western and Central African descent. The disease can lead to kidney cell injury, cell death and damage to the glomeruli, which filters blood in the kidney. This leads to abnormal amounts of protein in the urine and decreased kidney function.
Dr. Reshma Kewalramani, CEO of Vertex Pharmaceuticals discusses the company’s research into the underlying cause of APOL1-mediated kidney disease.
-
People with kidney disease often present with cognitive dysfunction ranging from mild impairment to dementia often effecting memory, language skills, attention span, and other functions including depression.
Nephrologist Mark Unruh, MD, Professor and Chair of the Department of Internal Medicine at the University of New Mexico, discusses cognitive impairment in patients with Chronic kidney disease and his research to find targeted interventions to address these challenges.
-
Human Acellular Vessels are bioengineered blood conduits which have shown great promise in clinical trials for vascular applications, including arteriovenous access for hemodialysis, peripheral arterial disease, and trauma repair.
Dr. Laura Niklason, Founder and CEO of Humacyte, discusses this promising technology and its recent deployment as humanitarian aid for repairing vascular trauma in Ukraine.
- Näytä enemmän
